Survival of Implanted Fetal Dopamine Cells and Neurologic Improvement 12 to 46 Months after Transplantation for Parkinson's Disease

New England Journal of Medicine

Volumn 327, Issue 22, 1992, Pages 1549-1555

  Freed, Curt R ^a   Breeze, Robert E ^a   Rosenberg, Neil L ^b   Schneck, Stuart A ^a   Kriek, Evelyn ^a   qi, Jian Xin ^a   Lone, Tim ^a   Zhang, Ying Bei ^a   Snyder, Jeffrey A ^a   Wells, Trent H ^c   Ramig, Lorraine Olson ^d   Thompson, Laetitia ^a   Mazziotta, John C ^e   Huang, S C ^e   Grafton, Scott T ^e   Brooks, David ^f   Sawle, Guy ^f   Schroter, Gerhard ^a   Ansari, Aftab A ^g  

^a UNIVERSITY OF COLORADO   (United States)

^b Swedish Medical Center   (United States)

^c Trent H Wells Inc ^*  (United States)

^d UNIVERSITY OF COLORADO   (United States)

^e UNIVERSITY OF CALIFORNIA   (United States)

^f HAMMERSMITH HOSPITAL   (United Kingdom)

^g EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARBIDOPA PLUS LEVODOPA; CYCLOSPORIN; PREDNISONE;

ADULT; AGED; ARTICLE; BRAIN TRANSPLANTATION; CAUDATE NUCLEUS; CLINICAL ARTICLE; DOPAMINERGIC NERVE CELL; DYSKINESIA; FEMALE; FETUS CELL; GRAFT SURVIVAL; HUMAN; HUMAN TISSUE; IMMUNOSUPPRESSIVE TREATMENT; MALE; MOTOR DYSFUNCTION; PARKINSON DISEASE; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PUTAMEN;

ACTIVITIES OF DAILY LIVING; ADULT; AGED; ANTIPARKINSON AGENTS; CAUDATE NUCLEUS; DOPAMINE; FEMALE; FETAL TISSUE TRANSPLANTATION; HUMAN; IMMUNOSUPPRESSION; MALE; MESENCEPHALON; MIDDLE AGE; NEUROLOGIC EXAMINATION; PARKINSON DISEASE; PUTAMEN; STEREOTAXIC TECHNIQUES; SUPPORT, NON-U.S. GOV'T; TIME FACTORS; TISSUE SURVIVAL; TOMOGRAPHY, EMISSION-COMPUTED; VIDEO RECORDING;

EID: 0026443974     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJM199211263272202     Document Type: Article

References (40)

1. Ehringer H, Hornykiewicz O. Verteilung von Noradrenalin und Dopamin (3-Hydroxytyramin) im Gehirn des Menschen und ihr Verhalten bei Erkrankungen des extrapyramidalen Systems. Klin Wochenschr 1960; 38: 1236–9.
2. Cotzias CG, Van Woert MH, Schiffer LM. Aromatic amino acids and modification of parkinsonism. N Engl J Med 1967; 276: 374–9.
3. Chase TN, Baronti F, Fabbrini G, Heuser IJ, Juncos JL, Mouradian MM. Rationale for continuous dopaminomimetic therapy of Parkinson's disease. Neurology 1989; 39: Suppl 2: 7–10.
4. Lieberman AN, Neophytides A, Leibowitz M, et al. Comparative efficacy of pergolide and bromocriptine in patients with advanced Parkinson's disease. In: Fahn S, Calne DB, Shoulson I, eds. Experimental therapeutics of movement disorders. Vol. 37 of Advances in neurology. New York: Raven Press, 1983:95–108.
5. Björklund A, Stenevi U. Reconstruction of the nigrostriatal dopamine pathway by intracerebral nigral transplants. Brain Res 1979; 177: 555–60.
6. Perlow MJ, Freed WJ, Hoffer BJ, Seiger A, Olson L, Wyatt RJ. Brain grafts reduce motor abnormalities produced by destruction of nigrostriatal dopamine system. Science 1979; 204: 643–7.
7. Bakay RAE, Fiandaca MS, Barrow DL, Schiff A, Collins DC. Preliminary report of the use of fetal tissue transplantation to correct MPTP-induced Parkinson-like syndrome in primates. Appl Neurophysiol 1985; 48: 358–61.
8. Redmond DE, Sladek JR Jr, Roth RH, et al. Fetal neuronal grafts in monkeys given methylphenyltetrahydropyridine. Lancet 1986; 1: 1125–7.
9. Freed CR, Richards JB, Sabol KE, Reite M. Fetal substantia nigra transplants lead to dopamine cell replacement and behavioral improvement in Bonnet monkeys with MPTP induced parkinsonism. In: Beart PM, Woodruff G, Jackson DM, eds. Pharmacology and functional regulation of dopaminergic neurons. London: Macmillan Press, 1988:353–63.
10. Bankiewicz KS, Plunkett RJ, Jacobowitz DM, et al. The effect of fetal mesencephalon implants on primate MPTP-induced parkinsonism: histochemical and behavioral studies. J Neurosurg 1990; 72: 231–44.
11. Dunnett SB, Annett LE. Nigral transplants in primate models of parkinsonism. In: Lindvall O, Björklund A, Widner H, eds. Intracerebral transplantation in movement disorders. Vol. 4 of Restorative neurology. Amsterdam: Elsevier, 1991:27–51.
12. Freed CR, Breeze R, Rosenberg N, Barrett JN, Rottenberg DA. Transplant of human fetal dopamine cells in a patient with Parkinson's disease. Clin Res 1989; 37: 527A. abstract.
13. Lindvall O, Rehncrona S, Brundin P, et al. Human fetal dopamine neurons grafted into the striatum in two patients with severe Parkinson's disease: a detailed account of methodology and a 6-month follow-up. Arch Neurol 1989; 46: 615–31.
14. Freed CR, Breeze RE, Rosenberg NL, et al. Transplantation of human fetal dopamine cells for Parkinson's disease: results at 1 year. Arch Neurol 1990; 47: 505–12.
15. Lindvall O, Brundin P, Widner H, et al. Grafts of fetal dopamine neurons survive and improve motor function in Parkinson's disease. Science 1990; 247: 574–7.
16. Madrazo I, Franco-Bourland R, Ostrosky-Solis F, et al. Fetal homotransplants (ventral mesencephalon and adrenal tissue) to the striatum of parkinsonian subjects. Arch Neurol 1990; 47: 1281–5.
17. Henderson BTH, Clough CG, Hughes RC, Hitchcock ER, Kenny BG. Implantation of human fetal ventral mesencephalon to the right caudate nucleus in advanced Parkinson's disease. Arch Neurol 1991; 48: 822–7.
18. Lindvall O, Widner H, Rehncrona S, et al. Transplantation of fetal dopamine neurons in Parkinson's disease: one-year clinical and neurophysiological observations in two patients with putaminal implants. Ann Neurol 1992; 31: 155–65.
19. Sawle GV, Bloomfield PM, Björklund A, et al. Transplantation of fetal dopamine neurons in Parkinson's disease: PET [18F]-6-L-fluorodopa studies in two patients with putaminal implants. Ann Neurol 1992; 31: 166–73.
20. Hoehn MM, Yahr MD. Parkinsonism: onset, progression and mortality. Neurology 1967; 17: 427–42.
21. Fahn S, Elton RL, Members of the UPDRS Development Committee. Unified Parkinson's Disease Rating Scale. In: Fahn S, Marsden CD, Calne DB, Goldstein M, eds. Recent developments in Parkinson's disease. Vol. 2. Florham Park, N.J.: Macmillan Healthcare Information, 1987:153–64.
22. Nahmias C, Garnett ES, Firnau G, Lang A. Striatal dopamine distribution in parkinsonian patients during life. J Neurol Sci 1985; 69: 223–30.
23. O'Rahilly R, Muller F. Developmental stages in human embryos. Carnegie Institution of Washington publication 637. Meriden, Conn.: Meriden-Stinehour Press, 1987.
24. Brundin P, Nilsson OG, Strecker RE, Lindvall O, Astedt B, Björklund A. Behavioural effects of human fetal dopamine neurons grafted in a rat model of Parkinson's disease. Exp Brain Res 1986; 65: 235–40.
25. Stromberg I, Bygdeman M, Goldstein M, Seiger A, Olson L. Human fetal substantia nigra grafted to the dopamine-denervated striatum of immunosuppressed rats: evidence for functional reinnervation. Neurosci Lett 1986; 71: 271–6.
26. Brundin P, Strecker RE, Widner H, et al. Human fetal dopamine neurons grafted in a rat model of Parkinson's disease: immunological aspects, spontaneous and drug-induced behaviour, and dopamine release. Exp Brain Res 1988; 70: 192–208.
27. Freeman TB, Spence MS, Boss BD, et al. Development of dopaminergic neurons in the human substantia nigra. Exp Neurol 1991; 113: 344–53.
28. Kawamoto JC, Barrett JN. Cryopreservation of primary neurons for tissue culture. Brain Res 1986; 384: 84–93.
29. Qi J-X, Patino P, Kriek E, Kruse C, Hutt C, Freed CR. Effects of refrigeration and tissue culture on dopamine production and transplant survival of fetal mesencephalic dopamine cells. Soc Neurosci Abstr 1991; 17: 347.
30. Freed CR, Breeze RE, Rosenberg NL, et al. Fetal neural implants for Parkinson's disease: results at 15 months. In: Lindvall O, Björklund A, Widner H, eds. Intracerebral transplantation in movement disorders. Vol. 4 of Restorative neurology. Amsterdam: Elsevier, 1991:69–77.
31. Christie-Pope BC, Burns RS, Whetsell WO Jr. Ultrastructural alterations induced by 1-methyl-4-phenylpyridinium (MPP+) in canine substantia nigra and rat mesencephalon in vitro. Exp Neurol 1989; 104: 235–40.
32. Kish SJ, Shannak K, Hornykiewicz O. Uneven pattern of dopamine loss in the striatum of patients with idiopathic Parkinson's disease: pathophysiologic and clinical implications. N Engl J Med 1988; 318: 876–80.
33. Björklund A, Schmidt RH, Stenevi U. Functional reinnervation of the neostriatum in the adult rat by use of intraparenchymal grafting of dissociated cell suspensions from the substantia nigra. Cell Tissue Res 1980; 212: 39–45.
34. Freed WJ, Dymecki J, Poltorak M, Rodgers CR. Intraventricular brain allografts and xenografts: studies of survival and rejection with and without systemic sensitization. In: Gash DM, Sladek JR, eds. Transplantation into the mammalian CNS. Vol. 78 of Progress in brain research. Amsterdam: Elsevier, 1988:233–41.
35. Goetz CG, Olanow CW, Koller WC, et al. Multicenter study of autologous adrenal medullary transplantation to the corpus striatum in patients with advanced Parkinson's disease. N Engl J Med 1989; 320: 337–41.
36. Allen GS, Burns RS, Tulipan NB, Parker RA. Adrenal medullary transplantation to the caudate nucleus in Parkinson's disease: initial clinical results in 18 patients. Arch Neurol 1989; 46: 487–91.
37. Bohn MC, Cupit L, Marciano F, Gash DM. Adrenal medulla grafts enhance recovery of striatal dopaminergic fibers. Science 1987; 237: 913–6.
38. Bankiewicz KS, Plunkett RJ, Jacobowitz DM, Kopin IJ, Oldfield EH. Fetal nondopaminergic neural implants in parkinsonian primates: histochemical and behavioral studies. J Neurosurg 1991; 74: 97–104.
39. Dunnett SB, Hernandez TD, Summerfield A, Jones GH, Arbuthnott G. Graft-derived recovery from 6-OHDA lesions: specificity of ventral mesencephalic graft tissues. Exp Brain Res 1988; 71: 411–24.
40. Patino P, Kriek EH, Hutt CJ, Qi JX, Freed CR. Short term corticosteroid treatment impairs survival of fetal dopamine cells transplanted into a rat model of Parkinson's disease. Soc Neurosci Abstracts 1992; 18: 59.